Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma
| Autor: | Oliver Blank, Lena Specht, Ina Monsef, Bastian von Tresckow, Andreas Engert, Nicole Skoetz |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Medicine General & Introductory Medical Sciences
Oncology medicine.medical_specialty Heart Diseases medicine.medical_treatment Infections 03 medical and health sciences 0302 clinical medicine Recurrence Internal medicine medicine Humans Pharmacology (medical) Survival analysis Randomized Controlled Trials as Topic Chemotherapy business.industry Standard treatment Hazard ratio Neoplasms Second Primary Chemoradiotherapy Combined Modality Therapy Hodgkin Disease Survival Analysis Chemotherapy regimen Surgery Radiation therapy 030220 oncology & carcinogenesis Relative risk Disease Progression business 030215 immunology |
| Zdroj: | The Cochrane Library |
| ISSN: | 1465-1858 |
| Popis: | Background Combined modality treatment consisting of chemotherapy followed by localised radiotherapy is the standard treatment for patients with early stage Hodgkin lymphoma (HL). However, due to long- term adverse effects such as secondary malignancies the role of radiotherapy has been questioned recently and some clinical study groups advocate chemotherapy only for this indication. Objectives To assess the effects of chemotherapy alone compared to chemotherapy plus radiotherapy in adults with early stage HL . Search methods For the or i ginal version of this review, we searched MEDLINE, Embase and CENTRAL as well as conference proceedings (American Society of Hematology, American Society of Clinical Oncology and International Symposium of Hodgkin Lymphoma) from January 1980 to November 2010 for randomised controlled trials (RCTs) comparing chemotherapy alone versus chemotherapy regimens plus radiotherapy. For the updated review we searched MEDLINE, CENTRAL and conference proceedings to December 2016. Selection criteria We included RCTs comparing chemotherapy alone with chemotherapy plus radiotherapy in patients with early stage HL. We excluded trials with more than 20% of patients in advanced stage. As the value of radiotherapy in addition to chemotherapy is still not clear, we also compared to more cycles of chemotherapy in the control arm. In this updated review, we also included a second comparison evaluating trials with varying numbers of cycles of chemotherapy between intervention and control arms, same chemotherapy regimen in both arms assumed. We excluded trials evaluating children only, therefore only trials involving adults are included in this updated review. Data collection and analysis Two review authors independently extracted data and assessed the quality of trials. We contacted study authors to obtain missing information. As effect measures we used hazard ratios (HR) for overall survival (OS) and progression-free survival (PFS) and risk ratios (RR) for response rates. Since not all trials reported PFS according to our definitions, we evaluated all similar outcomes (e.g. event-free survival) as PFS/tumour control. Main results Our search led to 5518 potentially relevant references. From these, we included seven RCTs in the analyses involving 2564 patients. In contrast to the first version of this review including five trials, we excluded trials randomising children. As a result, we excluded one trial from the former analyses and we identified three new trials. Five trials with 1388 patients compared the combination of chemotherapy alone and chemotherapy plus radiotherapy, with the same number of chemotherapy cycles in both arms. The addition of radiotherapy to chemotherapy has probably little or no difference on OS (HR 0.48; 95% confidence interval (CI) 0.22 to 1.06; P = 0.07, moderate- quality evidence), however two included trials had potential other high risk of bias due to a high number of patients not receiving planned radiotherapy. After excluding these trials in a sensitivity analysis, the results showed that the combination of chemotherapy and radiotherapy improved OS compared to chemotherapy alone (HR 0.31; 95% CI 0.19 to 0.52; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|